Fingerprint
Dive into the research topics of 'Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial
Khaled Ezzedine*, Elena Peeva, Yuji Yamaguchi, Lori Ann Cox, Anindita Banerjee, George Han, Iltefat Hamzavi, Anand K. Ganesan, Mauro Picardo, Diamant Thaçi, John E. Harris, Jung Min Bae, Katsuhiko Tsukamoto, Rodney Sinclair, Amit G. Pandya, Abigail Sloan, Dahong Yu, Kavita Gandhi, Michael S. Vincent, Brett King
*Corresponding author for this work
- Henri Mondor Hospital, University of Paris 12
- Pfizer Inc.
- Consultant to Pfizer
- Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
- Henry Ford Hospital
- University of California, Irvine
- IRCCS Istituto Dermatologico Santa Maria e San Gallicano – Roma
- University of Massachusetts Medical School
- Catholic University of Korea
- Yamanashi Prefectural Central Hospital
- Sinclair Dermatology
- Palo Alto Foundation Medical Group
- University of Texas Southwestern
- Yale University
19
Citations
(Scopus)